Tag Archives: lipid-lowering therapy

Introduction Ischaemic heart disease is the leading cause of death globally, responsible for 13% of all deaths in 2021.1 Acute coronary syndrome (ACS) represents a key opportunity for secondary prevention to reduce the risk of recurrent cardiovascular (CV) events.2 Lipid-lowering therapy (LLT) is central to this, with elevated levels of low-density lipoprotein cholesterol (LDL-C) being a key initiating factor in atherosclerosis:3 every 1 mmol/L reduction is associated with an approximate 22% decrease in the risk of major CV events.4 For patients with ACS, the National Institute for Health and Care Excellence (NICE) recommends:5,6 Early initi

No content available